In wake of PhII flop, Roche walks away from $350M Covid-19 an­tivi­ral pact

A month af­ter con­ced­ing a mid-stage fail­ure, Roche is drop­ping the Covid-19 an­tivi­ral pill it was joint­ly de­vel­op­ing with Atea.

The lit­tle biotech, which had re­ceived $350 mil­lion cash up­front from Roche last Oc­to­ber and raised an­oth­er $215 mil­lion ear­li­er in the pan­dem­ic, said it has both the fi­nan­cial re­sources and tal­ent to car­ry on with a planned Phase III tri­al and even­tu­al­ly steer the drug, AT527, to mar­ket. Roche had orig­i­nal­ly bought in to grab the ex-US rights.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.